Big pharma, Partnering, Pharma

Emergent acquires Eisai’s EV-035 series technology

Posted on 17 December 2014

Tags: , , ,

Evolva Holding announced that Emergent BioSolutions has acquired Evolva’s anti-bacterial programme, the EV-035 series.

Searching for more deal information? Current Partnering offers the following options:

  • CP Reports | Browse titles | Over 200 report titles that focus upon different deal types from licensing, co-promotion to distribution, biomarkers to drug delivery, oncology to psychiatry, all of which provide you with an insight into the latest life science deal making trends
  • Current Agreements | Login | Find out more | Updated daily by our industry analysts, our fully searchable life sciences intelligence database allows you to find deals and alliances dating as far back as 2000 saving you valuable time on your deal making research activities

 

The lead compound in the EV-035 series is the broad-spectrum antibiotic GC-072, which is being developed with US government biodefense funding.

For Evolva, this transaction is worth up to USD 70.5 million plus royalties.

Evolva will receive from Emergent an upfront payment of USD 1.5 million, an additional USD 4 million after the US government approves transfer of the GC-072 contract to Emergent, development milestone payments up to USD 65 million, and tiered royalties up to a maximum of 10% on product net sales generated from the EV-035 programme.

For further deal information visit Current Agreements (subscription required)

Related

Scorecard: Top partnering deals by value in 2014

View: Top pharmaceutical companies

View: Top biotech companies

Report: Top 50 Big Pharma Partnering and M&A Deal Trends

Report: Top 50 Big Biotech Partnering and M&A Deal Trends

Browse: Complete Current Partnering report catalog

 

Print Friendly, PDF & Email

Leave a Reply